Anticancer research · 2014
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Клиническое исследование I фазыКлиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iwahashi Shuichi, Utsunomiya Tohru, Imura Satoru, Morine Yuji, Ikemoto Tetsuya, Arakawa Yusuke, Saito Yu, Ishikawa Daichi, Shimada Mitsuo
Аннотация
BACKGROUND/AIM: Pancreatobiliary tract cancers are amongst the most aggressive human cancers. Histone deacetylase (HDAC) is well-known to be associated with tumorigenesis through epigenetic regulation and its inhibitors (HDACIs) induce differentiation and apoptosis of tumor cells. We conducted a clinical trial of combination therapy using valproic acid (VPA, a HDACI) and S-1, which is an oral fluoropyrimidine derivative consisting of 5-fluorouracil.
PATIENTS AND METHODS: Patients with advanced pancreatobiliary tract cancers were eligible for this clinical trial. Twelve patients, in whom a curative operation was not feasible, were enrolled in the study. Patients received S-1 orally at a daily dose of 80 mg/m(2) for 28 days, followed by a 14-day recovery period. They also received VPA orally at a total daily dose of 15 mg/kg, twice daily.
RESULTS: One patient had partial response (PR); ten patients were recorded with stable disease (SD); and one patient showed progressive disease (PD). Eight patients had clinically significant drug-related adverse events. The most frequent adverse events were platelet depletion and fatigue. Grade 3/4 adverse events, including anemia and platelet depletion, were observed. Significant increases in blood concentrations of VPA were confirmed 2 and 4 weeks after VPA administration.
CONCLUSION: Combination therapy of VPA and S-1 for patients with pancreatobiliary tract cancers had a manageable safety profile and preliminary antitumor activity.
PATIENTS AND METHODS: Patients with advanced pancreatobiliary tract cancers were eligible for this clinical trial. Twelve patients, in whom a curative operation was not feasible, were enrolled in the study. Patients received S-1 orally at a daily dose of 80 mg/m(2) for 28 days, followed by a 14-day recovery period. They also received VPA orally at a total daily dose of 15 mg/kg, twice daily.
RESULTS: One patient had partial response (PR); ten patients were recorded with stable disease (SD); and one patient showed progressive disease (PD). Eight patients had clinically significant drug-related adverse events. The most frequent adverse events were platelet depletion and fatigue. Grade 3/4 adverse events, including anemia and platelet depletion, were observed. Significant increases in blood concentrations of VPA were confirmed 2 and 4 weeks after VPA administration.
CONCLUSION: Combination therapy of VPA and S-1 for patients with pancreatobiliary tract cancers had a manageable safety profile and preliminary antitumor activity.